Medicine · 2026
Comparison of transcatheter aortic valve implantation and minimally invasive sutureless aortic valve replacement: A single-center study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Atilgan Kivanc, Bozbas Huseyin, Onuk Burak Emre, Kucuk Burhan, Er Zafer Cengiz, Aybek Tayfun
Аннотация
This study aims to compare the clinical outcomes of isolated aortic valve replacement using a sutureless bioprosthetic valve (Perceval) and Transcatheter Aortic Valve Implantation (TAVI). This single-center retrospective study evaluated 143 patients who underwent isolated surgical minimally invasive aortic valve replacement and TAVI procedures between January 2020 and February 2025. Demographic, intraoperative, and postoperative data as well as perioperative echocardiographic findings were analyzed and compared. The patients were divided into 2 groups: Sutureless (n = 73) and TAVI (n = 70). The Intensive care unit stay, intubation time, and hospital discharge time were significantly shorter in the TAVI group (P < .05). The requirement for inotropic support was also lower (2.8% vs 24.1%, P < .001). At the 30-day follow-up, the TAVI group had significantly lower mean and maximum transvalvular gradient. The need for pacemaker implantation was significantly higher in the TAVI group (P = .001). Pacemakers were implanted in 1.4% of patients in the sutureless group and 17.1% of patients in the TAVI group. The sutureless group had a significantly longer mean discharge time (5.47 ± 2.86 days) compared to the TAVI group (3.89 ± 2.93 days; P = .001). Similarly, intubation time was significantly longer in the sutureless group (11.90 ± 5.84 hours) compared to the TAVI group (3.37 ± 19.17 hours; P = .001). TAVI is a safe and effective alternative in appropriately selected patients, offering shorter operative times and improved early postprocedural recovery without compromising clinical or hemodynamic outcomes.